SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet (GOOG) is trending as discussions revolve around its AI capabilities, especially the Gemini 3 model, and potential market dominance. Community members are weighing bullish and bearish perspectives, with some pointing to new all-time highs and others anticipating a pullback. A multi-million dollar NATO cloud services deal has also sparked interest.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune ($ALT) is trending amid community discussions around potential buyout speculation, particularly involving Sanofi ($SNY), and anticipation for upcoming data releases. While some investors express optimism for a short squeeze and long-term growth driven by Pemvidutide's potential in MASH and obesity, others raise concerns about data integrity and trial design, sparking debate among bulls and bears.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus is trending amid discussions about its acquisition of Star 26 Capital and potential synergies within the aerospace and defense sectors. Community members are actively speculating on upcoming news and a possible short squeeze, with some expressing bullish sentiment based on the company's low float and perceived undervaluation. Despite recent volatility, investors are closely monitoring the stock's movement and awaiting further developments.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending due to a healthcare proposal delay following congressional backlash, sparking uncertainty about ACA subsidies. Community discussions revolve around the potential impact of this delay, with some anticipating a short squeeze while others express concern about the company's future prospects. The stock's significant price movement reflects the sensitivity to policy changes within the health insurance sector.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

AVGO is trending as investors assess its role in the AI infrastructure buildout, particularly following positive signals from top customers and upcoming earnings. Community members are discussing its potential to outperform peers and reach new highs, with some analysts setting bullish price targets. Despite market volatility, many see this dip as a buying opportunity before the December earnings.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst discussions around potential political implications and legal battles involving Donald Trump, with community members debating his influence and future prospects.  Some are focused on potential connections to ongoing investigations, while others are commenting on the stock's performance and its relationship to broader market trends and political events. The conversation reflects polarized opinions and speculation about the company's value and direction.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses potential ETF impacts and future price movements. Bullish sentiment is fueled by anticipation of increased adoption and institutional interest, while some traders express caution, citing XRP's historical price action and correlation with Bitcoin. Community members are debating short-term volatility versus long-term potential.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG Crypto, also known as Infinite Money Glitch, is trending due to its unique reward system that distributes $SOL to holders, generating excitement within its community. Community members highlight the potential for passive income through holding, regardless of price fluctuations. The broader discussion revolves around upcoming developments and the project's commitment to building innovative technology on the Solana blockchain, including its recent entry into the Cyberpunk Hackathon.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid discussions about potential investigations related to past associations and concerns about their influence on the market, particularly regarding Bitcoin and MicroStrategy. The community is actively debating JPM's role in market manipulation and its relationship with crypto, with some advocating for boycotts and shorting the stock. Additionally, JPM's adoption of blockchain and crypto as collateral is being discussed.

Monad

Monad is trending as it recently launched on Coinbase, generating excitement and discussion around its potential. The community is actively debating its market cap, possible price targets, and the implications of Coinbase's involvement in its initial offering. Some users express enthusiasm and long-term holding plans, while others caution about potential risks and pre-launch trading activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Magnetar Financial LLC Makes New $2.04 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL

Magnetar Financial LLC acquired a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the...

<ul class="summary-bullets"><li>Retail traders on Stocktwits drove a surge in takeover speculation amid Madrigal’s strong momentum around its liver-disease drug Rezdiffra.</li><li>Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.</li><li>Broader interest in metabolic and liver-disease treatments intensified after major breakthroughs across the obesity and inflammation drug space.</li></ul><p>Madrigal Pharmaceuticals Inc. trended on Stocktwits early Monday as retail traders fueled a burst of takeover speculation following weeks of positive clinical updates for its NASH drug Rezdiffra and rising analyst price targets.&nbsp;</p><h2 class="st-heading-2"><strong>Takeover Buzz Builds On Stocktwits</strong></h2><p>On Stocktwits, retail sentiment for Madrigal was ‘bullish’ amid ‘high’ message volume.</p><figure class="image"><img style="aspect-ratio:967/142;" src="https://news.stocktwits-cdn.com/mdgl_stock_png_f86f7ec52a.webp" alt="mdgl stock.png" width="967" height="142"><figcaption>MDGL sentiment and message volume as of November 24 | Source: Stocktwits</figcaption></figure><p>One user said the stock “could easily get bought out for 800+ a share,” while another argued that Madrigal’s valuation is “only 12B market cap for the first ever NASH drug that’s been doing crazy numbers.” Others posted that a “buyout [is] coming up,” while another user said any potential “Buy will be huge here.”</p><p><stembedurl>https://stocktwits.com/1986iamwallstreet/message/637238648</stembedurl></p><p><stembedurl>https://stocktwits.com/1986iamwallstreet/message/637238640</stembedurl></p><p><stembedurl>https://stocktwits.com/Wallst45/message/637236674</stembedurl></p><p><stembedurl>https://stocktwits.com/1986iamwallstreet/message/637234500</stembedurl></p><h2 class="st-heading-2"><strong>Analysts Lift Targets As New Rezdiffra Data Rolls Out</strong></h2><p>The retail surge followed another round of analyst upgrades. Earlier this month, Canaccord raised its price target on Madrigal to $587 from $526 and maintained a ‘Buy’ rating. H.C. Wainwright lifted its target to $568 from $500 following positive two-year data, and then again on Friday to $620 after speaking with key opinion leaders who reported “robust real-world uptake” across F2, F3 and F4c data.</p><p>Oppenheimer raised its target to $650 from $600 last Thursday while keeping an ‘Outperform’ rating, noting that new Rezdiffra updates strengthened confidence in commercial opportunities. Truist increased its target last Wednesday to $640 from $580 and reiterated a ‘Buy’ rating, citing increased conviction in Rezdiffra’s potential in MASH F4 patients.</p><h2 class="st-heading-2"><strong>Rezdiffra Data Shows Sustained Improvements</strong></h2><p>Madrigal presented new two-year data at the AASLD Liver Meeting this month, reporting that Rezdiffra improved liver stiffness, fibrosis biomarkers and markers associated with clinically significant portal hypertension risk. The company also reported sustained improvements in disease-specific quality-of-life measures in both cirrhotic and non-cirrhotic patients.&nbsp;</p><h2 class="st-heading-2"><strong>Metabolic Drugs Draw Market Attention</strong></h2><p>The broader metabolic-health category remained in focus after Eli Lilly surpassed a $1 trillion valuation on Friday, underscoring the rapid expansion of obesity and metabolism-related therapies. The surge in global demand for newer treatments has helped intensify investor attention on companies developing drugs for liver disease, metabolic dysfunction, and inflammation.</p><h2 class="st-heading-2"><strong>Obesity Developments Keep The Space In Focus</strong></h2><p>Updates from other obesity-related programs also kept the category in the spotlight. Altimmune recently reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/altimmune-stock-attracts-strong-retail-buzz-as-investors-count-down-to-48-week-data-for-its-fatty-liver-treatment/cLPklOxREI7">AI-based biopsy findings</a> from its Phase 2b IMPACT trial, which is being tested in obesity and MASH and showed fibrosis reductions in select pemvidutide groups.&nbsp;</p><p><a href="https://stocktwits.com/news-articles/markets/equity/viking-therapeutics-stock-soars-to-10-month-high-after-canaccord-boost-retail-traders-see-it-as-next-big-obesity-play/cLPBv8jRE3T">Viking Therapeutics</a> continued to draw retail interest earlier this month as its obesity pipeline gained momentum following recent sector dealmaking. Last month,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ventyx-biosciences-stock-retail-buzz-spikes-after-phase-2-win-in-obesity-and-heart-risk-study/cLG4epNR3A7">Ventyx Biosciences</a> posted positive Phase 2 data for its oral anti-inflammatory drug VTX3232 in participants with obesity and cardiovascular risk factors, reporting reductions in multiple inflammation biomarkers.</p><p><a href="https://stocktwits.com/symbol/MDGL">Madrigal Pharmaceuticals’ stock</a> has risen 78% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, Madrigal Pharmaceuticals logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum

Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.

Equity

Madrigal Pharmaceuticals (NASDAQ:MDGL) Given New $620.00 Price Target at HC Wainwright

HC Wainwright increased their target price on Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the stock a "buy" rating in a research note on Friday...

Carole Huntsman Sells 1,958 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) insider Carole Huntsman sold 1,958 shares of the firm's stock in a transaction on Friday, November 21st. The stock was sold at an...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $650.00

Oppenheimer upped their price target on Madrigal Pharmaceuticals from $600.00 to $650.00 and gave the stock an "outperform" rating in a research report on Thursday...

Truist Financial Boosts Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $640.00

Truist Financial upped their target price on Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the stock a "buy" rating in a research report on Wednesday...

Intech Investment Management LLC Sells 721 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

Intech Investment Management LLC decreased its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 7.4% during the 2nd quarter, according to the company in its most recent...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 12-Month High - Still a Buy?

Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 1-Year High - Here's What Happened...

Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC cut its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 12.2% during the second quarter, according to the company in its most recent Form 13F filing...

Richard Levy Sells 8,500 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director Richard Levy sold 8,500 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an...

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

MDGL
Madrigal Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MDGL News

MDGLMadrigal Pharmaceuticals Inc